Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed Executive Vice President, Chief ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

Hemophilia A Market Trends The report provides a detailed analysis of the current hemophilia A marketed drugs and late-stage pipeline drugs ...

Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.

H.C. Wainwright’s Patrick Trucchio reiterated his Buy rating on Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) and raised his ...

Alnylam’s pipeline continues to show promise beyond its ATTR franchise. The company has reported encouraging initial Phase 1 Multiple Ascending Dose (MAD) data for its Alzheimer’s disease ...

Alnylam is on track to meet its ambitious “2-2-5” pipeline and platform expansion goal announced at R&D Day in 2023. This includes filing Investigational New Drug (IND) applications for nine ...

In addition, we are on track to meet our ambitious pipeline and platform expansion ... Advancements Demonstrate Durable Leadership in TTR Alnylam scientists will provide an update on the TRITON ...

In addition, we are on track to meet our ambitious pipeline and platform expansion goals as we seek ... Nucresiran and Vutrisiran Advancements Demonstrate Durable Leadership in TTR Alnylam scientists ...

Moreover, Alnylam plans to scale its global market reach and further expand its pipeline. With more than 25 programs expected to be in the clinical stage by the end of 2025, the company is ...

The firm currently has four marketed products and several late-stage candidates in its pipeline. In addition to Onpattro's 2018 approval, Alnylam received approval in 2019 for Givlaari for acute ...